Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

Devax Receives IDE Approval To Commence DIVERGE II
Devax, Inc. announced that the U.S. Food and Drug Administration has conditionally approved an Investigational Device Exemption ("IDE") for its AXXESS™ Biolimus A9® Eluting Bifurcation Stent System (AXXESS System), allowing the company to initiate a pivotal clinical trial (DIVERGE II) of the device in the United States.
generic viagra online
Health Care Overhaul Ignores Illegal Immigrants
"As Congress wrangles with overhauling the health care system, there is one population not being discussed. No proposal for a national health plan would cover the nation"s estimated 11 million illegal immigrants," NPR reports. But "analysts say the notion that illegal immigrants drain the health system is overblown. Simply figuring out how many undocumented immigrants lack insurance is not easy," although the Lewin Group has estimated that the number is about 6.1 million, which is "only about half the total population of undocumented immigrants." John Sheils of the Lewin Group "says many illegal immigrants use false documents to work on the books, with regular tax deductions and benefits."
News of the day
Medtronic-Supported Clinical Trial Shows ICD Patients Less Likely To Develop Need For Pacing When Device Uses MVP(R) Mode
MVP® (Managed Ventricular Pacing), exclusive programming on Medtronic pacemakers, which is proven to be effective in reducing unnecessary pacing in pacemaker patients, was applied in the MVP Trial of implantable cardioverter-defibrillator (ICD) patients. Data from MVP trial, sponsored by Medtronic, Inc. (NYSE: MDT), were presented today as a late breaking clinical trial at Heart Rhythm 2009, the annual scientific sessions of the Heart Rhythm Society.
Oncology

Printing New Organs: Foundation Funds Medical Technology That Replicates Human Tissue

Methuselah Foundation has identified Organovo, Inc. as a leader in the extraordinary science of bio-printing. The US Department of Health and Human Services predicts: "Within 20 years regenerative medicine will be the standard of care for replacing all tissue/organ systems in the body." Organovo, with the support of Methuselah Foundation, is applying its breakthrough organ printing technologies to make that prediction a reality. "Methuselah Foundation, through the generosity of its donors, funds multiple strategies designed to extend healthy human life," according to Dave Gobel, Founder and CEO. The MLife Sciences program of Methuselah Foundation seeks long-term strategies to combat the progressive, degenerative process of biological aging. What is accepted as "aging" is a wide range of damage that occurs at the cellular level. Our bodies show and feel the results: functionality is lost and age-related frailty, disability and disease take over. Organovo is developing a very promising solution. Their 3-dimensional bio-printer lays down bio-ink that fuses into complex tissue, creating new tissue to replace diseased tissue. Rejection of transplanted tissue is not a concern; the cells that are used can be taken from youthful progenitor cells from the patient to replace the older diseased cells. Keith Murphy, CEO of Organovo, looks ahead, "Organovo has an exciting technology platform that has attracted broad investment at a time when capital is not free flowing. The technology has immediate applications in cardiovascular therapeutics, and as the platform of choice for three dimensional tissue development. In the future Organovo hopes to provide "Tissue on Demand" for surgical applications." Organovo, Inc. is a seed-stage regenerative medicine company that applies proprietary organ printing technology to solve critical problems in transplant medicine, cardiovascular medicine, tissue repair, and medical research. Keith Murphy, CEO of Organovo, looks ahead, "Organovo has an exciting technology platform that has attracted broad investment at a time when capital is not free flowing. The technology has immediate applications in cardiovascular therapeutics, and as the platform of choice for three dimensional tissue development. In the future Organovo hopes to provide "Tissue on Demand" for surgical applications." Organovo, Inc. is a seed-stage regenerative medicine company that applies proprietary organ printing technology to solve critical problems in transplant medicine, cardiovascular medicine, tissue repair, and medical research. Methuselah Foundation is a non-profit medical charity dedicated to extending healthy human life. The Foundation supports strategies that accelerate progress toward a comprehensive cure for age-related disease, disability, and suffering. Supported by the donations of individuals and organizations, the Foundation replaces resignation with an understanding of what is possible. Methuselah Foundation"s programs include near, mid-and long-term strategies that advance the mission of ending age-related disease through awareness, education, scientific research and direct community outreach Methuselah Foundation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009